AU5729294A - Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules - Google Patents

Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules

Info

Publication number
AU5729294A
AU5729294A AU57292/94A AU5729294A AU5729294A AU 5729294 A AU5729294 A AU 5729294A AU 57292/94 A AU57292/94 A AU 57292/94A AU 5729294 A AU5729294 A AU 5729294A AU 5729294 A AU5729294 A AU 5729294A
Authority
AU
Australia
Prior art keywords
conjugates
binding molecules
constructs including
including anti
constructs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57292/94A
Inventor
Tse Wen Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/981,276 external-priority patent/US6129916A/en
Priority claimed from US07/993,291 external-priority patent/US5872222A/en
Priority claimed from US08/011,130 external-priority patent/US6106835A/en
Priority claimed from US08/035,723 external-priority patent/US6197298B1/en
Priority claimed from US08/046,364 external-priority patent/US6117982A/en
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of AU5729294A publication Critical patent/AU5729294A/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU57292/94A 1992-11-25 1993-11-23 Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules Abandoned AU5729294A (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US07/981,276 US6129916A (en) 1991-04-19 1992-11-25 Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US981276 1992-11-25
US993291 1992-12-18
US07/993,291 US5872222A (en) 1991-04-19 1992-12-18 Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US011130 1993-01-28
US08/011,130 US6106835A (en) 1991-04-19 1993-01-28 Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US08/035,723 US6197298B1 (en) 1991-04-19 1993-03-23 Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
US035723 1993-03-23
US08/046,364 US6117982A (en) 1991-04-19 1993-04-08 Conjugates of microbeads and antibodies specific for T lymphocytes and their use as in vivo immune modulators
US046364 1993-04-08
US8274293A 1993-06-25 1993-06-25
US082742 1993-06-25
PCT/US1993/011434 WO1994012196A1 (en) 1992-11-25 1993-11-23 Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules

Publications (1)

Publication Number Publication Date
AU5729294A true AU5729294A (en) 1994-06-22

Family

ID=27555692

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57292/94A Abandoned AU5729294A (en) 1992-11-25 1993-11-23 Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules

Country Status (2)

Country Link
AU (1) AU5729294A (en)
WO (1) WO1994012196A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
EP0824594B1 (en) * 1995-05-04 2005-04-06 The United States of America as Representend by The Secretary of the Navy Improved methods for transfecting t cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
WO1998038513A1 (en) * 1997-02-26 1998-09-03 Khaw Ban An Signal enhancement of bispecific antibody-polymer probe for immunoassay use
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
HUE028467T2 (en) 2004-02-26 2016-12-28 Immunovative Therapies Ltd Methods for preparing T-cells for cell therapy
EP3202895A1 (en) * 2004-03-01 2017-08-09 Immunovative Therapies, Ltd. A composition for use in cell therapy and methods for its preparation
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2167536A1 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
CA2838046C (en) 2011-05-03 2023-03-07 Immunovative Therapies, Ltd. Induction of il-12 using immunotherapy
US10350242B2 (en) 2011-05-03 2019-07-16 Immunovative Therapies Ltd. Methods for handling biological drugs containing living cells
EP2711418B1 (en) * 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
WO2018237148A1 (en) 2017-06-21 2018-12-27 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
ZA91463B (en) * 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody

Also Published As

Publication number Publication date
WO1994012196A1 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
AU5729294A (en) Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
GB9316989D0 (en) Binding molecules
AU4241197A (en) Personal care article with aperture aligned for receiving fecal material
AU3220593A (en) Soluble mhc molecules and their uses
AU1645895A (en) CTLA4 molecules and IL4-binding molecules and uses thereof
AU3655899A (en) Modified immunoglobulin molecules and methods for use thereof
AU3379193A (en) Antigen binding proteins and methods for their production
AU4518196A (en) Adjuvant-incorporated cellular antigens: conjugation and methods
AU1116297A (en) Flk-1 binding protein
GB9105245D0 (en) Binding molecules
PL314908A1 (en) Humanised antibodies and their application
AU4972096A (en) Peptides and compounds that bind to sh2 domains
AU5093796A (en) Human transcription factors and binding assays
AU2099795A (en) Cyano compounds and preparations thereof
AU671148C (en) Binding element
AU7422496A (en) NM03 antibody materials and methods
AU6711994A (en) Rapamycin conjugates and antibodies
AU1317695A (en) Conjugates consisting of peptidic t cell antigens and cell binding partners and their use for therapy
HUP9602910A3 (en) Non-linear crystals and using them
AU1538497A (en) Anti-gp46 antibodies and fragments thereof and their use
AU2698095A (en) Modulators of multidrug resistance transporters
ZA963437B (en) The binding of documents
AU4836693A (en) Device for carrying leaves and other materials
AU4970196A (en) Dna constructs and plants incorporating them
AU4584196A (en) Adhesive composition and use thereof